KRAS and colorectal carcinoma: A phase 1 clinical study is currently investigating the mRNA-5671/V941 vaccine either alone or in combination with anti-PD-1 (pembrolizumab) in patients diagnosed with advanced or metastatic microsatellite stable CRC harboring one of the four KRAS mutations (G12D, G12V, G13D, or G12C) and specific HLA types, including HLA-A11:01 or HLA C08:02 (NCT03948763).